Penn State Milton S. Hershey Medical Center

Running trials

• Not yet recruiting

  A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

  NCT07789015· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

  NCT07310420· Phase 1· TerSera Therapeutics LLC· Source

• Not yet recruiting

  Accurate Planning and Guidance of Bronchoscopy for Lung Cancer Management

  NCT07822126· Penn State University· Source

• Recruiting

  Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin

  NCT07441681· Phase 3· NRG Oncology· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

• Recruiting

  Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

  NCT07225621· Phase 2· Alpheus Medical, Inc.· Source

• Recruiting

  Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  NCT07198074· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07225946· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

  NCT06686771· Phase 3· Canadian Cancer Trials Group· Source

• Recruiting

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· Phase 3· Incyte Corporation· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

  NCT06524544· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

  NCT07061977· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07184996· Phase 3· Sanofi· Source

• Recruiting

  Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

  NCT07097142· Phase 3· NRG Oncology· Source

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  NCT07184931· Phase 3· Sanofi· Source

• Recruiting

  A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

  NCT06774131· Phase 3· UroGen Pharma Ltd.· Source

• Recruiting

  Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

  NCT06532279· Phase 2· NRG Oncology· Source

• Recruiting

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· Phase 3· BeOne Medicines· Source

• Recruiting

  Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

  NCT06770582· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Rapid Evacuation and Access of Cerebral Hemorrhage Trial

  NCT06870812· Emory University· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  NCT06881784· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819878· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  NCT06580314· Phase 3· NRG Oncology· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

  NCT06742996· Phase 3· BeOne Medicines· Source

• Recruiting

  Transitional Care Program for Fluid Overload in Cirrhosis

  NCT06174272· Milton S. Hershey Medical Center· Source

• Recruiting

  Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

  NCT06482853· Early phase 1· Milton S. Hershey Medical Center· Source

• Recruiting

  Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

  NCT06526195· Abbott Medical Devices· Source

• Active, not recruiting

  Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

  NCT06500455· Phase 3· NRG Oncology· Source

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

  NCT06457503· Phase 4· Coherus Oncology, Inc.· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

  NCT06568237· Phase 2· Teva Branded Pharmaceutical Products R&D LLC· Source

• Recruiting

  Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  NCT06317649· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  NCT05554406· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  NCT05554393· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

  NCT06096844· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Skin-interfaced Colorimetric Bifluidic Sweat Sensor Device for the Diagnosis of Cystic Fibrosis (CF)

  NCT05998629· Milton S. Hershey Medical Center· Source

• Recruiting

  Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  NCT06324357· Phase 1/2· Boehringer Ingelheim· Source

• Recruiting

  Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

  NCT06205485· Phase 3· Canadian Cancer Trials Group· Source

• Recruiting

  MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  NCT05564390· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

  NCT06208150· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

  NCT05946213· Phase 3· NRG Oncology· Source

• Recruiting

  Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy

  NCT05866419· Alcyone Therapeutics, Inc· Source

• Recruiting

  TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

  NCT05848687· Phase 1/2· Tanja Andrea Gruber· Source

• Recruiting

  Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  NCT05879926· Phase 3· NRG Oncology· Source

• Recruiting

  Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

  NCT05673148· Phase 2· Alliance for Clinical Trials in Oncology· Source

Showing 50 of 157.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer6 recruiting
• Bladder cancer5 recruiting
• Lung cancer5 recruiting
• Ovarian cancer5 recruiting
• Acute myeloid leukaemia4 recruiting
• Head and neck cancer4 recruiting
• Metastatic breast cancer4 recruiting
• Prostate cancer4 recruiting
• Crohn's disease3 recruiting
• High blood pressure3 recruiting
• Childhood cancers2 recruiting
• Endometrial cancer2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Glioblastoma2 recruiting
• Heart failure2 recruiting
• Kidney cancer2 recruiting
• Liver cirrhosis2 recruiting
• Multiple myeloma2 recruiting
• Myelodysplastic syndromes2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Triple-negative breast cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Amyloidosis1 recruiting
• Cervical cancer1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• COPD1 recruiting
• Cystic fibrosis1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Mantle cell lymphoma1 recruiting
• Meningioma1 recruiting
• Myasthenia gravis1 recruiting
• Obesity1 recruiting
• Obstructive sleep apnoea1 recruiting
• Pancreatic cancer1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Spinal muscular atrophy1 recruiting
• Stroke1 recruiting
• Thyroid cancer1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  A 12-week Pilot Nutrition Intervention for Children With New Diagnosis of Stage 3 Type 1 Diabetes (T1D)

  NCT06640478· Milton S. Hershey Medical Center· Source

• Completed

  Piloting a Virtual Navigation (VN) System for Bronchoscopic Lung Nodule Sampling

  NCT05599321· Penn State University· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Terminated

  A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

  NCT05574010· Phase 1/2· Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA· Source

• Completed

  A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

  NCT05375903· Phase 1· UroGen Pharma Ltd.· Source

• Terminated

  Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial

  NCT04825275· Early phase 1· Milton S. Hershey Medical Center· Source

• Terminated

  Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)

  NCT05237284· Phase 2· Sanofi· Source

• Completed

  Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)

  NCT05232929· Phase 4· Genentech, Inc.· Source

• Completed

  Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

  NCT03941860· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Califormula Study: Calibrated Formula Feeding to Optimize Infant Growth

  NCT05104073· Milton S. Hershey Medical Center· Source

• Completed

  A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

  NCT04921969· Phase 3· Incyte Corporation· Source

• Completed

  Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT04708782· Phase 3· United Therapeutics· Source

• Completed

  Decreasing Stress in Diabetes

  NCT04016415· Milton S. Hershey Medical Center· Source

• Terminated

  Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

  NCT04365868· Phase 2/3· Galectin Therapeutics Inc.· Source

• Completed

  A Neurobiological Model of Anhedonia

  NCT05629520· Milton S. Hershey Medical Center· Source

• Completed

  Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

  NCT03974113· Phase 2/3· Genzyme, a Sanofi Company· Source

• Completed

  Inositol Supplementation to Treat PCOS (INSUPP-PCOS)

  NCT03864068· Phase 2· Milton S. Hershey Medical Center· Source

• Withdrawn

  Knee Osteoarthritis Outcome Measures in Arthritic Patients With Osteoporosis

  NCT03217513· Edward Fox· Source

• Completed

  Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

  NCT03836209· Phase 2· PrECOG, LLC.· Source

• Completed

  Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

  NCT04037254· Phase 1/2· NRG Oncology· Source

• Completed

  Angiotensin-(1-7) and Energy Expenditure in Human Obesity

  NCT03777215· Early phase 1· Amy Arnold· Source

• Completed

  STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA

  NCT03988309· Pacific Edge Limited· Source

• Completed

  Effects of Heating on Exercise Pressor Reflex in Peripheral Artery Disease: Exercise Ability

  NCT03900832· Early phase 1· Milton S. Hershey Medical Center· Source

• Terminated

  Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

  NCT03199885· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

  NCT03827798· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) - Long Term Follow-Up

  NCT03555331· Milton S. Hershey Medical Center· Source

• Completed

  Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

  NCT03258554· Phase 2/3· National Cancer Institute (NCI)· Source

• Recruiting

  Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction

  NCT02901184· Phase 3· Uppsala University· Source

• Terminated

  A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

  NCT03288545· Phase 1/2· Astellas Pharma Global Development, Inc.· Source

• Terminated

  Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

  NCT02928497· Boston Scientific Corporation· Source

• Completed

  Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

  NCT02089217· Mayo Clinic· Source

• Completed

  Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer

  NCT02254278· Phase 2· NRG Oncology· Source

• Completed

  MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer

  NCT01805076· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Completed

  Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

  NCT02003209· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

  NCT01950390· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

  NCT01824875· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Completed

  Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

  NCT01730937· Phase 3· Radiation Therapy Oncology Group· Source

• Completed

  S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

  NCT01809691· Phase 3· SWOG Cancer Research Network· Source

• Completed

  S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

  NCT01120249· Phase 3· SWOG Cancer Research Network· Source

• Completed

  Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

  NCT01167712· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

  NCT01149083· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

  NCT00936390· Phase 3· Radiation Therapy Oncology Group· Source

• Completed

  Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

  NCT00861705· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

  NCT00632853· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

  NCT00379340· Phase 3· Children's Oncology Group· Source

• Completed

  Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

  NCT00352534· Phase 3· Children's Oncology Group· Source

• Completed

  Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

  NCT00107198· Phase 2· Children's Oncology Group· Source

• Completed

  Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

  NCT00217737· Phase 3· National Cancer Institute (NCI)· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Peripheral artery disease7 works · 1 trial